C M Gibson

Summary

Affiliation: Brigham and Women's Hospital
Country: USA

Publications

  1. ncbi Pharmacokinetic evaluation of rivaroxaban for the treatment of acute coronary syndromes
    Lakshmi Gopalakrishnan
    Harvard Medical School, Beth Israel Deaconess Medical Center, Cardiovascular Division, Department of Medicine, Boston, MA 02115, USA
    Expert Opin Drug Metab Toxicol 8:889-900. 2012
  2. ncbi Trends in reperfusion strategies, door-to-needle and door-to-balloon times, and in-hospital mortality among patients with ST-segment elevation myocardial infarction enrolled in the National Registry of Myocardial Infarction from 1990 to 2006
    C Michael Gibson
    Cardiovascular Division, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA
    Am Heart J 156:1035-44. 2008
  3. ncbi Association of non-steroidal anti-inflammatory drugs with outcomes in patients with ST-segment elevation myocardial infarction treated with fibrinolytic therapy: an ExTRACT-TIMI 25 analysis
    C Michael Gibson
    TIMI Study Group, Cardiovascular Division, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, 350 Longwood Avenue, First Floor, Boston, MA 02115, USA
    J Thromb Thrombolysis 27:11-7. 2009
  4. ncbi Relation of hyperemic epicardial flow to outcomes among patients with ST-segment elevation myocardial infarction receiving fibrinolytic therapy
    C Michael Gibson
    TIMI Study Group, Department of Medicine, Beth Israel Deaconess Medical Center, Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts, USA
    Am J Cardiol 101:1232-8. 2008
  5. ncbi Relationship of creatine kinase-myocardial band release to Thrombolysis in Myocardial Infarction perfusion grade after intracoronary stent placement: an ESPRIT substudy
    C Michael Gibson
    Harvard Clinical Research Institute, 900 Commonwealth Ave, 2nd Floor, Boston, MA 02215, USA
    Am Heart J 143:106-10. 2002
  6. ncbi Association of impaired thrombolysis in myocardial infarction myocardial perfusion grade with ventricular tachycardia and ventricular fibrillation following fibrinolytic therapy for ST-segment elevation myocardial infarction
    C Michael Gibson
    TIMI Study Group, Beth Israel Deaconess Medical Center, Boston, Massachusetts 02115, USA
    J Am Coll Cardiol 51:546-51. 2008
  7. ncbi Precordial ST-segment depression in inferior myocardial infarction is associated with slow flow in the non-culprit left anterior descending artery
    C Michael Gibson
    Harvard Clinical Research Institute and Brigham and Women s Hospital, Boston, MA 02215, USA
    J Thromb Thrombolysis 13:9-12. 2002
  8. ncbi Distance from the coronary ostium to the culprit lesion in acute ST-elevation myocardial infarction and its implications regarding the potential prevention of proximal plaque rupture
    C Michael Gibson
    TIMI Study Group, Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, 350 Longwood Avenue, Boston, MA 02115, USA
    J Thromb Thrombolysis 15:189-96. 2003
  9. ncbi Diagnostic and prognostic value of ambulatory ECG (Holter) monitoring in patients with coronary heart disease: a review
    C Michael Gibson
    PERFUSE Core Laboratory and Data Coordinating Center, Harvard Medical School, 350 Longwood Avenue, First Floor, Boston, MA 02115, USA
    J Thromb Thrombolysis 23:135-45. 2007
  10. ncbi Usefulness of clopidogrel in abolishing the increased risk of reinfarction associated with higher platelet counts in patients with ST-elevation myocardial infarction (results from CLARITY-TIMI 28)
    C Michael Gibson
    TIMI Study Group, Boston, Massachusetts, USA
    Am J Cardiol 98:761-3. 2006

Detail Information

Publications115 found, 100 shown here

  1. ncbi Pharmacokinetic evaluation of rivaroxaban for the treatment of acute coronary syndromes
    Lakshmi Gopalakrishnan
    Harvard Medical School, Beth Israel Deaconess Medical Center, Cardiovascular Division, Department of Medicine, Boston, MA 02115, USA
    Expert Opin Drug Metab Toxicol 8:889-900. 2012
    ....
  2. ncbi Trends in reperfusion strategies, door-to-needle and door-to-balloon times, and in-hospital mortality among patients with ST-segment elevation myocardial infarction enrolled in the National Registry of Myocardial Infarction from 1990 to 2006
    C Michael Gibson
    Cardiovascular Division, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA
    Am Heart J 156:1035-44. 2008
    ..As such, door-to-needle (D2N) and door-to-balloon (D2B) times have become metrics of quality of care and targets for intense quality improvement...
  3. ncbi Association of non-steroidal anti-inflammatory drugs with outcomes in patients with ST-segment elevation myocardial infarction treated with fibrinolytic therapy: an ExTRACT-TIMI 25 analysis
    C Michael Gibson
    TIMI Study Group, Cardiovascular Division, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, 350 Longwood Avenue, First Floor, Boston, MA 02115, USA
    J Thromb Thrombolysis 27:11-7. 2009
    ....
  4. ncbi Relation of hyperemic epicardial flow to outcomes among patients with ST-segment elevation myocardial infarction receiving fibrinolytic therapy
    C Michael Gibson
    TIMI Study Group, Department of Medicine, Beth Israel Deaconess Medical Center, Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts, USA
    Am J Cardiol 101:1232-8. 2008
    ..Hyperemic flow with associated impaired myocardial perfusion may be a marker of more extensive downstream microembolization...
  5. ncbi Relationship of creatine kinase-myocardial band release to Thrombolysis in Myocardial Infarction perfusion grade after intracoronary stent placement: an ESPRIT substudy
    C Michael Gibson
    Harvard Clinical Research Institute, 900 Commonwealth Ave, 2nd Floor, Boston, MA 02215, USA
    Am Heart J 143:106-10. 2002
    ..Given the high rates of Thrombolysis in Myocardial Infarction (TIMI) grade 3 flow after PCI, we hypothesized that abnormalities in tissue level perfusion would instead explain CK-MB release...
  6. ncbi Association of impaired thrombolysis in myocardial infarction myocardial perfusion grade with ventricular tachycardia and ventricular fibrillation following fibrinolytic therapy for ST-segment elevation myocardial infarction
    C Michael Gibson
    TIMI Study Group, Beth Israel Deaconess Medical Center, Boston, Massachusetts 02115, USA
    J Am Coll Cardiol 51:546-51. 2008
    ..The goal of this analysis was to evaluate the association of impaired Thrombolysis In Myocardial Infarction myocardial perfusion grade (TMPG) with sustained ventricular tachycardia (VT) or ventricular fibrillation (VF)...
  7. ncbi Precordial ST-segment depression in inferior myocardial infarction is associated with slow flow in the non-culprit left anterior descending artery
    C Michael Gibson
    Harvard Clinical Research Institute and Brigham and Women s Hospital, Boston, MA 02215, USA
    J Thromb Thrombolysis 13:9-12. 2002
    ..To determine whether APSTD is associated with abnormal blood flow in the uninvolved or non-culprit LAD, we assessed TIMI flow grades and corrected TIMI frame counts (CTFC) in both the culprit and non-culprit arteries of IMI patients...
  8. ncbi Distance from the coronary ostium to the culprit lesion in acute ST-elevation myocardial infarction and its implications regarding the potential prevention of proximal plaque rupture
    C Michael Gibson
    TIMI Study Group, Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, 350 Longwood Avenue, Boston, MA 02115, USA
    J Thromb Thrombolysis 15:189-96. 2003
    ....
  9. ncbi Diagnostic and prognostic value of ambulatory ECG (Holter) monitoring in patients with coronary heart disease: a review
    C Michael Gibson
    PERFUSE Core Laboratory and Data Coordinating Center, Harvard Medical School, 350 Longwood Avenue, First Floor, Boston, MA 02115, USA
    J Thromb Thrombolysis 23:135-45. 2007
    ..Indeed, many ongoing and upcoming trials of pharmacotherapy include ischemia on Holter monitoring as an endpoint...
  10. ncbi Usefulness of clopidogrel in abolishing the increased risk of reinfarction associated with higher platelet counts in patients with ST-elevation myocardial infarction (results from CLARITY-TIMI 28)
    C Michael Gibson
    TIMI Study Group, Boston, Massachusetts, USA
    Am J Cardiol 98:761-3. 2006
    ..Clopidogrel therapy abolishes this increase in the risk of reinfarction as platelet counts increase. These data are consistent with a putative role of platelets in reinfarction...
  11. ncbi Association of a pulsatile blood flow pattern on coronary arteriography and short-term clinical outcomes in acute myocardial infarction
    C Michael Gibson
    Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital, Boston, Massachusetts 02115, USA
    J Am Coll Cardiol 43:1170-6. 2004
    ....
  12. ncbi Early and long-term clinical outcomes associated with reinfarction following fibrinolytic administration in the Thrombolysis in Myocardial Infarction trials
    C Michael Gibson
    Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital, 350 Longwood Avenue, 1st Floor, Boston, MA 02115, USA
    J Am Coll Cardiol 42:7-16. 2003
    ..We hypothesized that early recurrent myocardial infarction (MI) following fibrinolytic administration would be assessed with higher mortality at both 30 days and 2 years...
  13. ncbi Association of a negative residual stenosis following rescue/adjunctive percutaneous coronary intervention with impaired myocardial perfusion and adverse outcomes among ST-segment elevation myocardial infarction patients
    C Michael Gibson
    Cardiovascular Division, Beth Israel Deaconess Medical Center, Harvard Medical School, 350 Longwood Avenue, Boston, MA 02115, USA
    J Am Coll Cardiol 45:357-62. 2005
    ....
  14. ncbi Methodologic and clinical validation of the TIMI myocardial perfusion grade in acute myocardial infarction
    C Michael Gibson
    Department of Medicine, Brigham and Women s Hospital, USA
    J Thromb Thrombolysis 14:233-7. 2002
    ..Thus, DSA validates that TMPG 3 is associated with normal kinetics of myocardial perfusion, and this likely accounts for the low (0.7%) 30 day mortality observed among those patients with TFG 3 and TMPG 3...
  15. ncbi NRMI and current treatment patterns for ST-elevation myocardial infarction
    C Michael Gibson
    Harvard Medical School, Boston Mass, USA
    Am Heart J 148:S29-33. 2004
    ..In all, 1600 hospitals have participated and >2.2 million patients have been followed. This paper highlights some of our discoveries pertaining to ST-segment elevation and subsequent contributions to patient care...
  16. ncbi Antiplatelet therapy: anti-ischemic benefits versus bleeding risk
    C Michael Gibson
    Division of Cardiology, Beth Israel Deaconess Medical Center, Boston, Massachusetts 02115, USA
    J Interv Cardiol 21:S3-9. 2008
    ..Issues related to safety include timing of the dose, duration of infusion, drug compatibility, errors in estimating a patient's weight and/or age, failure to adjust the dosage based upon renal function, and errors in drug preparation...
  17. ncbi Relationship of the TIMI myocardial perfusion grades, flow grades, frame count, and percutaneous coronary intervention to long-term outcomes after thrombolytic administration in acute myocardial infarction
    C Michael Gibson
    TIMI Study Group, Department of Medicine, Brigham and Women s Hospital, Boston, Mass 02215, USA
    Circulation 105:1909-13. 2002
    ....
  18. ncbi Rationale and design of the INFUSE-AMI study: A 2 × 2 factorial, randomized, multicenter, single-blind evaluation of intracoronary abciximab infusion and aspiration thrombectomy in patients undergoing percutaneous coronary intervention for anterior ST-seg
    C Michael Gibson
    Cardiovascular Division, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA
    Am Heart J 161:478-486.e7. 2011
    ....
  19. ncbi Benefit of transferring ST-segment-elevation myocardial infarction patients for percutaneous coronary intervention compared with administration of onsite fibrinolytic declines as delays increase
    Duane S Pinto
    Division of Cardiology, Interventional Section, Beth Israel Deaconess Medical Center, 185 Pilgrim Rd, Boston MA 02115, USA
    Circulation 124:2512-21. 2011
    ..We hypothesized that delays resulting from transfer would reduce the survival advantage of X-PCI compared with O-FT...
  20. ncbi Intracoronary eptifibatide bolus administration during percutaneous coronary revascularization for acute coronary syndromes with evaluation of platelet glycoprotein IIb/IIIa receptor occupancy and platelet function: the Intracoronary Eptifibatide (ICE) Tr
    Albert J Deibele
    350 Longwood Ave, First Floor, Boston, MA 02115, USA
    Circulation 121:784-91. 2010
    ....
  21. ncbi Effect of intensive statin therapy on clinical outcomes among patients undergoing percutaneous coronary intervention for acute coronary syndrome. PCI-PROVE IT: A PROVE IT-TIMI 22 (Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis I
    C Michael Gibson
    TIMI Study Group, Cardiovascular Division, Department of Medicine, Beth Israel Deaconess Medical Center, Boston, Massachusetts 02115, USA
    J Am Coll Cardiol 54:2290-5. 2009
    ....
  22. ncbi Can we replace the 90-minute thrombolysis in myocardial infarction (TIMI) flow grades with those at 60 minutes as a primary end point in thrombolytic trials? TIMI Study Group
    C M Gibson
    Department of Medicine, The University of California San Francisco, 94118, USA
    Am J Cardiol 87:450-3, A6. 2001
    ..Thus, the 60-minute angiographic end point appears to be a valid alternative to that at 90 minutes and may permit earlier decisions regarding post-thrombolytic intervention...
  23. ncbi Correlates of coronary blood flow before and after percutaneous coronary intervention and their relationship to angiographic and clinical outcomes in the RESTORE trial. Randomized Efficacy Study of Tirofiban for Outcomes and REstenosis
    C Michael Gibson
    Harvard Clinical Research Institute, Boston, Mass 02215, USA
    Am Heart J 144:130-5. 2002
    ..We sought to evaluate the correlates of pre- and post-PTCA coronary blood flow to shed light on potential modifiable determinants...
  24. ncbi Impact of contrast agent type (ionic versus nonionic) used for coronary angiography on angiographic, electrocardiographic, and clinical outcomes following thrombolytic administration in acute myocardial infarction
    C M Gibson
    Harvard Clinical Research Institute, Boston, Massachusetts 02215, USA
    Catheter Cardiovasc Interv 53:6-11. 2001
    ....
  25. ncbi Rationale and design of the Anti-Xa therapy to lower cardiovascular events in addition to standard therapy in subjects with acute coronary syndrome-thrombolysis in myocardial infarction 51 (ATLAS-ACS 2 TIMI 51) trial: a randomized, double-blind, placebo-c
    C Michael Gibson
    TIMI Study Group, Brigham and Women s Hospital, Boston, MA, USA
    Am Heart J 161:815-821.e6. 2011
    ..9%] vs 62/1160 [5.5%]; hazard ratio 0.69, [95% CI 0.50-0.96], P = .027). Two candidate doses of rivaroxaban were selected for further evaluation in a pivotal phase 3...
  26. ncbi Combination reperfusion therapy with abciximab and reduced dose reteplase: results from TIMI 14. The Thrombolysis in Myocardial Infarction (TIMI) 14 Investigators
    E M Antman
    Brigham and Women s Hospital, Boston, MA 02115, USA
    Eur Heart J 21:1944-53. 2000
    ..reteplase when administered in combination with abciximab were associated with higher TIMI 3 flow rates than reported previously for reduced doses of reteplase without abciximab and were at least as high as for full dose reteplase alone..
  27. ncbi Myoglobin, creatine kinase MB, and cardiac troponin-I to assess reperfusion after thrombolysis for acute myocardial infarction: results from TIMI 10A
    M J Tanasijevic
    Clinical Laboratories, Brigham and Women s Hospital, Boston, MA 02115, USA
    Am Heart J 134:622-30. 1997
    ..The availability of a reliable, noninvasive serum marker of reperfusion may permit early identification of patients with occlusion after thrombolysis who might benefit from further interventions...
  28. ncbi Abciximab improves both epicardial flow and myocardial reperfusion in ST-elevation myocardial infarction. Observations from the TIMI 14 trial
    J A de Lemos
    Cardiovascular Division, Brigham and Women s Hospital, Boston Massachusetts, USA
    Circulation 101:239-43. 2000
    ..We determined whether the combination of abciximab plus reduced-dose tPA provided additional benefit in terms of myocardial reperfusion, as evidenced by greater resolution of ST elevation...
  29. ncbi Combination therapy with abciximab reduces angiographically evident thrombus in acute myocardial infarction: a TIMI 14 substudy
    C M Gibson
    Harvard Clinical Research Institute, Boston, Massachusetts, USA
    Circulation 103:2550-4. 2001
    ..These data provide a pathophysiological link between platelet inhibition, reduced thrombus, and improvements in both epicardial and microvascular perfusion in AMI...
  30. ncbi Rescue angioplasty in the thrombolysis in myocardial infarction (TIMI) 4 trial
    C M Gibson
    Department of Medicine, The Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts, USA
    Am J Cardiol 80:21-6. 1997
    ....
  31. ncbi Myoglobin, creatine-kinase-MB and cardiac troponin-I 60-minute ratios predict infarct-related artery patency after thrombolysis for acute myocardial infarction: results from the Thrombolysis in Myocardial Infarction study (TIMI) 10B
    M J Tanasijevic
    Clinical Laboratories, Brigham and Women s Hospital, Boston, Massachusetts 02115, USA
    J Am Coll Cardiol 34:739-47. 1999
    ....
  32. ncbi Enoxaparin as adjunctive antithrombin therapy for ST-elevation myocardial infarction: results of the ENTIRE-Thrombolysis in Myocardial Infarction (TIMI) 23 Trial
    Elliott M Antman
    Cardiovascular Division, Brigham and Women s Hospital, 75 Francis St, Boston, Mass, USA
    Circulation 105:1642-9. 2002
    ..ENTIRE-TIMI 23 evaluated enoxaparin with full-dose tenecteplase (TNK) and half-dose TNK plus abciximab...
  33. ncbi Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban
    C P Cannon
    Cardiovascular Division, Brigham and Women s Hospital, Boston, MA 02115, USA
    N Engl J Med 344:1879-87. 2001
    ..There is continued debate as to whether a routine, early invasive strategy is superior to a conservative strategy for the management of unstable angina and myocardial infarction without ST-segment elevation...
  34. ncbi Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation
    Marc S Sabatine
    TIMI Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, Boston, MA 02115, USA
    N Engl J Med 352:1179-89. 2005
    ....
  35. ncbi Early coronary intervention following pharmacologic therapy for acute myocardial infarction (the combined TIMI 10B-TIMI 14 experience)
    M J Schweiger
    Department of Medicine, Baystate Medical Center, Springfield, Massachusetts 01199, USA
    Am J Cardiol 88:831-6. 2001
    ..e., TIMI 3 flow at 90 minutes) who did not undergo revascularization (p = 0.02). Thus, early PCI following AMI is associated with excellent outcomes. Randomized trials of an early invasive strategy following thrombolysis are warranted...
  36. ncbi Angiographic predictors of reocclusion after thrombolysis: results from the Thrombolysis in Myocardial Infarction (TIMI) 4 trial
    C M Gibson
    Department of Medicine, Brigham and Women s Hospital, Boston, Massachusetts
    J Am Coll Cardiol 25:582-9. 1995
    ..This study attempted to determine which lesion characteristics are associated with reocclusion by 18 to 36 h...
  37. ncbi Heart-type fatty acid binding protein as a marker of reperfusion after thrombolytic therapy
    J A de Lemos
    Department of Medicine, Brigham and Women s Hospital, Boston, MA, USA
    Clin Chim Acta 298:85-97. 2000
    ..Despite a favorable kinetic profile, however, H-FABP does not appear to represent a significant advance over myoglobin in the noninvasive detection of reperfusion after thrombolysis...
  38. ncbi Myoglobin levels at 12 hours identify patients at low risk for 30-day mortality after thrombolysis in acute myocardial infarction: a Thrombolysis in Myocardial Infarction 10B substudy
    V S Srinivas
    Division of Cardiology, Department of Medicine, Albert Einstein College of Medicine/Montefiore Medical Center, Bronx, NY, USA
    Am Heart J 142:29-36. 2001
    ..A low 12-hour myoglobin level (< or = 239 ng/mL in this substudy) identifies such patients at low risk and could potentially assist in early risk stratification and triage after ST-segment elevation myocardial infarction...
  39. ncbi Determinants of improvement in epicardial flow and myocardial perfusion for ST elevation myocardial infarction; insights from TIMI 14 and InTIME-II
    E M Antman
    Cardiovascular Division, Brigham and Women's Hospital, Boston, MA 02115, USA
    Eur Heart J 23:928-33. 2002
    ..To adjust for determinants of success of reperfusion regimens, phase II trials evaluating new drug combinations should consider using a randomization scheme that stratifies patients based on infarct location and time from symptoms...
  40. ncbi Angiographic and clinical outcomes in patients receiving low-molecular-weight heparin versus unfractionated heparin in ST-elevation myocardial infarction treated with fibrinolytics in the CLARITY-TIMI 28 Trial
    Marc S Sabatine
    Thrombolysis in Myocardial Infarction TIMI Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts, USA
    Circulation 112:3846-54. 2005
    ..Whether these advantages translate into greater infarct-related artery patency and fewer adverse clinical events in patients with ST-elevation myocardial infarction (STEMI) receiving fibrinolytic therapy remains under study...
  41. ncbi Association between platelet receptor occupancy after eptifibatide (integrilin) therapy and patency, myocardial perfusion, and ST-segment resolution among patients with ST-segment-elevation myocardial infarction: an INTEGRITI (Integrilin and Tenecteplase
    C Michael Gibson
    TIMI Study Group and the Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Mass, USA
    Circulation 110:679-84. 2004
    ....
  42. ncbi Combination reperfusion therapy with eptifibatide and reduced-dose tenecteplase for ST-elevation myocardial infarction: results of the integrilin and tenecteplase in acute myocardial infarction (INTEGRITI) Phase II Angiographic Trial
    Robert P Giugliano
    TIMI Study Group, Brigham and Women s Hospital, Boston, Massachusetts 02115, USA
    J Am Coll Cardiol 41:1251-60. 2003
    ..The goal of this study was to evaluate combinations of eptifibatide with reduced-dose tenecteplase (TNK) in ST-elevation myocardial infarction (STEMI)...
  43. ncbi Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, phase II trial
    J L Mega
    TIMI Study Group, Boston, MA, USA
    Lancet 374:29-38. 2009
    ..However, its use after acute coronary syndromes has not been investigated. In this setting, we assessed the safety and efficacy of rivaroxaban and aimed to select the most favourable dose and dosing regimen...
  44. ncbi Combined assessment of thrombolysis in myocardial infarction flow grade, myocardial perfusion grade, and ST-segment resolution to evaluate epicardial and myocardial reperfusion
    Robert P Giugliano
    TIMI Study Group, Cardiovascular Division, Brigham and Women s Hospital, 350 Longwood Avenue, 1st Floor Offices, Boston, MA 02115, USA
    Am J Cardiol 93:1362-7, A5-6. 2004
    ..This new end point is proposed to evaluate the success of reperfusion therapy in patients who undergo early angiography...
  45. ncbi Effects of pretreatment with clopidogrel on nonemergent percutaneous coronary intervention after fibrinolytic administration for ST-segment elevation myocardial infarction: a Clopidogrel as Adjunctive Reperfusion Therapy-Thrombolysis in Myocardial Infarct
    C Michael Gibson
    TIMI Study Group and Cardiovascular Division, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02115, USA
    Am Heart J 155:133-9. 2008
    ..We sought to evaluate the effect of nonemergent PCI on mortality among patients with STEMI treated with fibrinolytic administration and the consequence of clopidogrel pretreatment on this effect...
  46. ncbi Early initiation of eptifibatide in the emergency department before primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: results of the Time to Integrilin Therapy in Acute Myocardial Infarction (TITAN)-TIMI 34 trial
    C Michael Gibson
    TIMI Study Group, Cardiovascular Division, Brigham and Women s Hospital and the Department of Medicine, Harvard Medical School, Boston, MA, USA
    Am Heart J 152:668-75. 2006
    ..Early restoration of epicardial flow before primary percutaneous coronary intervention (PCI) for ST-segment elevation myocardial infarction (STEMI) has been associated with improved clinical outcomes...
  47. ncbi Association between thrombolysis in myocardial infarction myocardial perfusion grade, biomarkers, and clinical outcomes among patients with moderate- to high-risk acute coronary syndromes: observations from the randomized trial to evaluate the relative PR
    C Michael Gibson
    TIMI Study Group, Cardiovascular Division, Brigham and Women s Hospital, Boston, MA, USA
    Am Heart J 152:756-61. 2006
    ..A variety of imaging modalities have implicated impaired myocardial perfusion in the pathogenesis of acute coronary syndromes (ACSs)...
  48. ncbi Angiographic and clinical outcomes among patients with acute coronary syndromes presenting with isolated anterior ST-segment depression: a TRITON-TIMI 38 (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel
    Yuri B Pride
    Cardiovascular Division, Department of Medicine, Beth Israel Deaconess Medical Center, Boston, Massachusetts 02115, USA
    JACC Cardiovasc Interv 3:806-11. 2010
    ..This study sought to determine angiographic and clinical outcomes among patients with acute coronary syndrome (ACS) presenting with isolated anterior ST-segment depression on 12-lead electrocardiogram (ECG)...
  49. ncbi Intravenous platelet blockade with cangrelor during PCI
    Deepak L Bhatt
    VA Boston Healthcare System and Brigham and Women s Hospital, Boston, MA 02132, USA
    N Engl J Med 361:2330-41. 2009
    ..Intravenous cangrelor, a rapid-acting, reversible adenosine diphosphate (ADP) receptor antagonist, might reduce ischemic events during percutaneous coronary intervention (PCI)...
  50. ncbi Weight-adjusted dosing of TNK-tissue plasminogen activator and its relation to angiographic outcomes in the thrombolysis in myocardial infarction 10B trial. TIMI 10B Investigators
    C M Gibson
    Department of Medicine, Allegheny General Hospital, Pittsburgh, Pennsylvania 15212, USA
    Am J Cardiol 84:976-80. 1999
    ..The greater effectiveness of thrombolysis must be weighed against any increase in risk...
  51. ncbi Coronary artery injection technique: a quantitative in vivo investigation using modern catheters
    J T Dodge
    Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts 02115, USA
    Cathet Cardiovasc Diagn 44:34-9. 1998
    ..001) over a longer period (P < 0.0001) more slowly (P < 0.0001). Catheter size and the injected vessel's location and anatomy significantly affect coronary catheterization injection technique...
  52. ncbi Angiographic and clinical characteristics associated with the development of Q-wave and non-Q-wave myocardial infarction in the thrombolysis in myocardial infarction (TIMI) 14 trial
    Sabina A Murphy
    TIMI Study Group, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA
    Am Heart J 146:42-7. 2003
    ..No differences in mortality or recurrent MI rates were detected in patients who sustained a Q-wave MI and patients in whom a Q-wave MI did not evolve in the modern thrombolytic era...
  53. ncbi Angiographic perfusion score in patients treated with PCI at late angiography following fibrinolytic administration for ST-segment elevation myocardial infarction is associated with morbidity and mortality at 30 days
    Yuri B Pride
    Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA
    J Thromb Thrombolysis 26:106-12. 2008
    ..In STEMI patients treated with fibrinolytic therapy and scheduled for angiography later during hospital admission, however, the association of later indices of flow and perfusion with clinical outcomes has not been assessed...
  54. ncbi Intracoronary bolus administration of eptifibatide during percutaneous coronary stenting for non ST elevation myocardial infarction and unstable angina
    Albert J Deibele
    Division of Cardiology, Duluth Clinic, Duluth, Minnesota, USA
    J Thromb Thrombolysis 22:47-50. 2006
    ..Larger prospective and randomized studies are warranted to further explore the efficacy of this strategy.Intracoronary eptifibatide administration during PCI for UA/NSTEMI is feasible and safe...
  55. ncbi Timing of glycoprotein IIb/IIIa inhibitor use and outcomes among patients with non-ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention (results from CRUSADE)
    Pierluigi Tricoci
    Division of Cardiology, and Duke Clinical Research Institute, Duke University Medical Center, Durham, NC, USA
    Am J Cardiol 99:1389-93. 2007
    ..In conclusion, in this observational analysis, overall ischemic outcomes were similar between the 2 groups, but clinical trials are needed to solve the controversy over optional timing of GP IIb/IIIa inhibitor use...
  56. ncbi A randomized trial to evaluate the relative protection against post-percutaneous coronary intervention microvascular dysfunction, ischemia, and inflammation among antiplatelet and antithrombotic agents: the PROTECT-TIMI-30 trial
    C Michael Gibson
    TIMI Study Group, Cardiovascular Division, Brigham and Women s Hospital and Department of Medicine, Harvard Medical School, Boston, Massachusetts, USA
    J Am Coll Cardiol 47:2364-73. 2006
    ....
  57. ncbi The role of clopidogrel in early and sustained arterial patency after fibrinolysis for ST-segment elevation myocardial infarction: the ECG CLARITY-TIMI 28 Study
    Benjamin M Scirica
    TIMI Study Group, Cardiovascular Division, Brigham and Women s Hospital, Boston, Massachusetts 02115, USA
    J Am Coll Cardiol 48:37-42. 2006
    ..This study was designed to determine the relationship between clopidogrel and early ST-segment resolution (STRes) and the interaction of the two with clinical outcomes after fibrinolysis...
  58. ncbi Association of the timing of ST-segment resolution with TIMI myocardial perfusion grade in acute myocardial infarction
    C Michael Gibson
    TIMI Study Group, The Department of Medicine, Brigham and Women's Hospital, Boston, Mass, USA
    Am Heart J 147:847-52. 2004
    ....
  59. ncbi Myonecrosis following stent placement: association between impaired TIMI myocardial perfusion grade and MRI visualization of microinfarction
    James W Choi
    Division of Cardiology, Northwestern University Feinberg School of Medicine, Chicago, Illinois 60611, USA
    Catheter Cardiovasc Interv 61:472-6. 2004
    ..03). These data support the theory that distal embolization and microvascular obstruction are associated with myonecrosis following otherwise successful coronary stent placement and provide further insight into its pathophysiology...
  60. ncbi Sequential risk stratification using TIMI risk score and TIMI flow grade among patients treated with fibrinolytic therapy for ST-segment elevation acute myocardial infarction
    Dimitrios Karmpaliotis
    Department of Medicine, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA
    Am J Cardiol 94:1113-7. 2004
    ..High TRS at presentation is associated with abnormal myocardial perfusion, even after adjusting for possible confounders...
  61. ncbi Evaluation of the association of proximal coronary culprit artery lesion location with clinical outcomes in acute myocardial infarction
    Juhana Karha
    TIMI Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts, USA
    Am J Cardiol 92:913-8. 2003
    ..In patients with a LAD culprit lesion, proximal lesion location is a multivariate correlate of adverse outcomes even after adjustment for coronary blood flow and other covariates...
  62. ncbi Differential expression of cardiac biomarkers by gender in patients with unstable angina/non-ST-elevation myocardial infarction: a TACTICS-TIMI 18 (Treat Angina with Aggrastat and determine Cost of Therapy with an Invasive or Conservative Strategy-Thrombo
    Stephen D Wiviott
    Cardiovascular Division, Brigham and Women s Hospital, 75 Francis St, Boston, Mass 02115, USA
    Circulation 109:580-6. 2004
    ..We sought to examine the relationship between gender and cardiac biomarkers in patients with unstable angina (UA)/non-ST-segment elevation myocardial infarction (NSTEMI)...
  63. ncbi Use of reperfusion therapies in elderly patients with acute myocardial infarction
    B G Angeja
    Department of Medicine, University of California, San Francisco, Moffitt Hospital, 94143 0124, USA
    Drugs Aging 18:587-96. 2001
    ..Finally, newer, more fibrin-specific thrombolytics may decrease the bleeding risk associated with thrombolytic therapy...
  64. ncbi Use of risk stratification to identify patients with unstable angina likeliest to benefit from an invasive versus conservative management strategy
    D H Solomon
    Division of Pharmacoepidemiology and Pharmacoeconomics, Boston, Massachusetts 02115, USA
    J Am Coll Cardiol 38:969-76. 2001
    ..This study was designed to determine whether patient characteristics collected at presentation can identify which patients benefit from immediate coronary angiography and revascularization...
  65. ncbi Safety of the weight-adjusted dosing regimen of tenecteplase in the ASSENT-Trial
    B G Angeja
    Cardiovascular Division, University of California San Francisco, San Francisco, California 94143 0124, USA
    Am J Cardiol 88:1240-5. 2001
    ..33). Adjustment for small baseline differences in this randomized sample did not change the results. Thus, across the range of estimated weight categories corresponding to each TNK dose, TNK is as safe and effective as t-PA...
  66. ncbi Effect of preoperative statin therapy and cardiac outcomes after coronary artery bypass grafting
    M I Dotani
    Department of Medicine, West Virginia University Hospitals, Morgantown, USA
    Am J Cardiol 86:1128-30, A6. 2000
    ..Preoperative statin administration in this analysis showed improved cardiovascular outcomes after coronary artery bypass graft surgery, including death, myocardial infarction, unstable angina, and arrhythmias...
  67. ncbi Relationship between baseline white blood cell count and degree of coronary artery disease and mortality in patients with acute coronary syndromes: a TACTICS-TIMI 18 (Treat Angina with Aggrastat and determine Cost of Therapy with an Invasive or Conservati
    Marc S Sabatine
    TIMI Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital, 75 Francis Street, Boston, MA 02115, USA
    J Am Coll Cardiol 40:1761-8. 2002
    ....
  68. ncbi Association between duration of tirofiban therapy before percutaneous intervention and tissue level perfusion (a TACTICS-TIMI 18 substudy)
    C Michael Gibson
    Department of Medicine, Brigham and Women s Hospital, 350 Longwood Avenue, Boston, MA 02115, USA
    Am J Cardiol 94:492-4. 2004
    ....
  69. ncbi Global outcomes of ST-elevation myocardial infarction: comparisons of the Enoxaparin and Thrombolysis Reperfusion for Acute Myocardial Infarction Treatment-Thrombolysis In Myocardial Infarction study 25 (ExTRACT-TIMI 25) registry and trial
    Benjamin A Steinberg
    Thrombolysis in Myocardial Infarction Study Group, Cardiovascular Division, Brigham and Women s Hospital and Department of Medicine, Harvard Medical School, Boston, MA 02115, USA
    Am Heart J 154:54-61. 2007
    ..We hypothesized that adjustment for baseline risk would minimize such variations...
  70. ncbi Reperfusion strategies for ST-elevation myocardial infarction
    Saumil R Shah
    Division of Cardiology, Beth Israel Deaconess Medical Center, 350 Longwood Avenue, First Floor, Boston, MA 02115, USA
    Curr Cardiol Rep 9:281-8. 2007
    ..The evidence supporting facilitated PCI varies according to the pharmacologic regimen at this time...
  71. ncbi Clinical, procedural, and pharmacologic correlates of acute and subacute stent thrombosis: results of a multicenter case-control study with 145 thrombosis events
    Michael J Rinaldi
    Beth Israel Deaconess Medical Center, Boston, MA, USA
    Am Heart J 155:654-60. 2008
    ....
  72. ncbi Predictors of the rise in vWF after ST elevation myocardial infarction: implications for treatment strategies and clinical outcome: An ENTIRE-TIMI 23 substudy
    Kausik K Ray
    TIMI Study Group and Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital Harvard Medical School, Boston, MA, USA
    Eur Heart J 26:440-6. 2005
    ....
  73. ncbi Predicting irreversible left ventricular dysfunction after acute myocardial infarction
    Daniel R Frisch
    Division of Cardiology, Thomas Jefferson University, Philadelphia, Pennsylvania, USA
    Am J Cardiol 103:1206-9. 2009
    ..3. The presence of all 3 features had a positive predictive value of 100%. These findings may identify a high-risk group of patients who might benefit from early aggressive therapy such as an implantable cardioverter-defibrillator...
  74. ncbi Administration of intracoronary eptifibatide during ST-elevation myocardial infarction
    Duane S Pinto
    Beth Israel Deaconess Medical Center, Division of Cardiology, Boston, Massachusetts, USA
    Am J Cardiol 96:1494-7. 2005
    ..Further prospective randomized trials are warranted to evaluate the efficacy and safety of intracoronary eptifibatide...
  75. ncbi B-type natriuretic peptide at presentation and prognosis in patients with ST-segment elevation myocardial infarction: an ENTIRE-TIMI-23 substudy
    Jessica L Mega
    TIMI Study Group, Boston, Massachusetts 02115, USA
    J Am Coll Cardiol 44:335-9. 2004
    ..These data support the value of combining markers of hemodynamic stress with traditional approaches to risk assessment in acute myocardial infarction...
  76. ncbi Time for contrast material to traverse the epicardial artery and the myocardium in ST-segment elevation acute myocardial infarction versus unstable angina pectoris/non-ST-elevation acute myocardial infarction
    Graham C Wong
    TIMI Study Group and the Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA
    Am J Cardiol 91:1163-7. 2003
    ..These data provide insight into potential mechanistic differences between these 2 clinical syndromes...
  77. ncbi Design and rationale of Clopidogrel as Adjunctive Reperfusion Therapy-Thrombolysis in Myocardial Infarction (CLARITY-TIMI) 28 trial
    Marc S Sabatine
    TIMI Study Group, Cardiovascular Division, Brigham and Women s Hospital, Boston, MA 02115, USA
    Am Heart J 149:227-33. 2005
    ..We hypothesize that the addition of clopidogrel to standard fibrinolytic therapy in patients with acute STEMI will improve reperfusion...
  78. ncbi Association of duration of symptoms at presentation with angiographic and clinical outcomes after fibrinolytic therapy in patients with ST-segment elevation myocardial infarction
    C Michael Gibson
    TIMI Study Group, Cardiovascular Division, Brigham and Women s Hospital, Boston, Massachusetts, USA
    J Am Coll Cardiol 44:980-7. 2004
    ....
  79. ncbi Relationship of symptom-onset-to-balloon time and door-to-balloon time with mortality in patients undergoing angioplasty for acute myocardial infarction
    C P Cannon
    Cardiovascular Division, Brigham and Women s Hospital, 75 Francis St, Boston, MA 02115, USA
    JAMA 283:2941-7. 2000
    ..Rapid time to treatment with thrombolytic therapy is associated with lower mortality in patients with acute myocardial infarction (MI). However, data on time to primary angioplasty and its relationship to mortality are inconclusive...
  80. ncbi Relation between myocardial infarct size and ventricular tachyarrhythmia among patients with preserved left ventricular ejection fraction following fibrinolytic therapy for ST-segment elevation myocardial infarction
    Yuri B Pride
    Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA
    Am J Cardiol 104:475-9. 2009
    ....
  81. ncbi Influence of race on death and ischemic complications in patients with non-ST-elevation acute coronary syndromes despite modern, protocol-guided treatment
    Marc S Sabatine
    TIMI Study Group, Cardiovascular Division, Brigham and Women s Hospital, Boston, Mass 02115
    Circulation 111:1217-24. 2005
    ..Whether the disparate outcomes exist independently of potential biases in treatment patterns remains unclear...
  82. ncbi Impact of saphenous vein graft radiographic markers on clinical events and angiographic parameters
    Stephen A Olenchock
    Cardiothoracic Surgery Department, Tufts University School of Medicine and Caritas St Elizabeth s Medical Center, Boston, Massachusetts, USA
    Ann Thorac Surg 85:520-4. 2008
    ..The goal of the present analysis was to evaluate the association of SVG markers with clinical outcomes and graft patency...
  83. ncbi Has my patient achieved adequate myocardial reperfusion?
    C Michael Gibson
    TIMI Study Group, Harvard Medical School, USA
    Circulation 108:504-7. 2003
  84. ncbi The early glycoprotein IIb/IIIa inhibition in non-ST-segment elevation acute coronary syndrome (EARLY ACS) trial: a randomized placebo-controlled trial evaluating the clinical benefits of early front-loaded eptifibatide in the treatment of patients with n
    Robert P Giugliano
    TIMI Study Group, Boston, MA 02115, USA
    Am Heart J 149:994-1002. 2005
    ..However, the guidelines are not explicit regarding the timing of initiation of GpIIb-IIIa antagonists, and there is marked variation in clinical practice regarding their use...
  85. ncbi Prasugrel versus clopidogrel in patients with acute coronary syndromes
    Stephen D Wiviott
    Brigham and Women s Hospital and Harvard Medical School, Boston, MA 02115, USA
    N Engl J Med 357:2001-15. 2007
    ..Dual-antiplatelet therapy with aspirin and a thienopyridine is a cornerstone of treatment to prevent thrombotic complications of acute coronary syndromes and percutaneous coronary intervention...
  86. ncbi Angiographically evident thrombus following fibrinolytic therapy is associated with impaired myocardial perfusion in STEMI: a CLARITY-TIMI 28 substudy
    Ajay J Kirtane
    Cardiovascular Division, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA
    Eur Heart J 27:2040-5. 2006
    ..This finding emphasizes the roles of platelet aggregation and distal embolization in the pathogenesis of microvascular dysfunction in STEMI...
  87. ncbi Minimal ST-segment deviation: a simple, noninvasive method for identifying patients with a patent infarction-related artery after fibrinolytic administration
    Howard A Cooper
    Cardiovascular Division, Brigham and Women s Hospital, Boston, Mass 02115, USA
    Am Heart J 144:790-5. 2002
    ..The sum of ST-segment resolution (sum-STRES) has a high positive predictive value (PPV) for a patent IRA, but is quite time-consuming...
  88. ncbi C-reactive protein and cardiovascular outcomes in smokers versus nonsmokers in non-ST-elevation acute coronary syndrome (from the TACTICS-TIMI 18 trial)
    Nazanin Moghbeli
    Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA
    Am J Cardiol 96:635-8. 2005
    ..0 vs 5.1 mg/L, p <0.001). CRP was associated with adverse cardiovascular outcomes in smokers and nonsmokers, even when adjusted for the presence of pulmonary disease...
  89. ncbi Impact of iodinated contrast injections on percent diameter coronary arterial stenosis and implications for trials of intracoronary pharmacotherapies in patients with ST-elevation myocardial infarction
    C Michael Gibson
    Cardiovascular Division, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA
    Am J Cardiol 100:13-7. 2007
    ....
  90. ncbi Percutaneous coronary intervention in patients receiving enoxaparin or unfractionated heparin after fibrinolytic therapy for ST-segment elevation myocardial infarction in the ExTRACT-TIMI 25 trial
    C Michael Gibson
    Cardiovascular Division, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA
    J Am Coll Cardiol 49:2238-46. 2007
    ....
  91. ncbi Relationship between uncontrolled risk factors and C-reactive protein levels in patients receiving standard or intensive statin therapy for acute coronary syndromes in the PROVE IT-TIMI 22 trial
    Kausik K Ray
    Brigham and Women's Hospital/Harvard Medical School, Boston, Massachusetts, USA
    J Am Coll Cardiol 46:1417-24. 2005
    ....
  92. ncbi Dose escalation trial of the efficacy, safety, and pharmacokinetics of a novel fibrinolytic agent, BB-10153, in patients with ST elevation MI: results of the TIMI 31 trial
    C Michael Gibson
    TIMI Study Group, Cardiovascular Division, Brigham and Women s Hospital and the Department of Medicine, Harvard Medical School, 350 Longwood Avenue, First Floor, Boston, MA, 02115, USA
    J Thromb Thrombolysis 22:13-21. 2006
    ..BB-10153 also has a relatively long half-life of 3-4 hours, which may also limit the potential for early reocclusion [1, 2]...
  93. ncbi Issues in the assessment of the safety and efficacy of tenecteplase (TNK-tPA)
    C M Gibson
    Harvard Clinical Research Institute, Boston, Massachusetts 02215, USA
    Clin Cardiol 24:577-84. 2001
    ..Tenecteplase has demonstrated clinical equivalence to t-PA, but with a wider therapeutic margin of safety...
  94. ncbi Outcome of patients with acute myocardial infarction who are ineligible for primary angioplasty trials
    H L Dauerman
    Cardiovascular Division, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts, USA
    Catheter Cardiovasc Interv 49:237-43. 2000
    ..Cathet. Cardiovasc. Intervent. 49:237-243, 2000...
  95. ncbi Recombinant tissue-type plasminogen activators: "time matters"
    V Kunadian
    Institute of Cellular Medicine, Newcastle University and Cardiothoracic Centre, Newcastle upon Tyne, UK
    Drugs Today (Barc) 47:559-70. 2011
    ..This article discusses the use of recombinant tissue plasminogen activators for the management of patients with acute STEMI and the importance of restoring optimal timely reperfusion of the myocardium...
  96. ncbi Outcomes among patients with ST-segment-elevation myocardial infarction presenting to interventional hospitals with and without on-site cardiac surgery
    Yuri B Pride
    Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA
    Circ Cardiovasc Qual Outcomes 2:574-82. 2009
    ..The quality of care and safety and efficacy of pPCI at hospitals without on-site open heart surgery (No-OHS hospitals) remains an area of active investigation...
  97. ncbi Outcomes among patients with non-ST-segment elevation myocardial infarction presenting to interventional hospitals with and without on-site cardiac surgery
    Yuri B Pride
    Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA
    JACC Cardiovasc Interv 2:944-52. 2009
    ....
  98. ncbi Angiographic perfusion score: an angiographic variable that integrates both epicardial and tissue level perfusion before and after facilitated percutaneous coronary intervention in acute myocardial infarction
    C Michael Gibson
    TIMI Study Group, The Department of Medicine, Brigham and Women's Hospital, Boston, Mass, USA
    Am Heart J 148:336-40. 2004
    ..Partial or full angiographic perfusion scores are associated with a halving of infarct size, and no patients with full angiographic perfusion died...
  99. ncbi Early dynamic risk stratification with baseline troponin levels and 90-minute ST-segment resolution to predict 30-day cardiovascular mortality in ST-segment elevation myocardial infarction: analysis from CLopidogrel as Adjunctive ReperfusIon TherapY (CLAR
    Matthew W Sherwood
    TIMI Study Group, Division of Cardiovascular Medicine, Brigham and Women s Hospital and Harvard Medical School, Boston, MA 02115, USA
    Am Heart J 159:964-971.e1. 2010
    ..The incremental prognostic use of the initial magnitude of troponin elevation and its value in conjunction with ST-segment resolution (STRes) in ST elevation myocardial infarction (STEMI) is less well defined...
  100. ncbi Association of culprit lesion calcium with angiographic and clinical outcomes in patients with ST-elevation myocardial infarction treated with fibrinolytic therapy
    Ajay J Kirtane
    Department of Medicine, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA
    Am J Cardiol 95:337-42. 2005
    ..2, p = 0.045). CLC is independently associated with indexes of poorer epicardial flow and a higher incidence of adverse clinical outcomes after fibrinolytic administration in patients who have ST-elevation myocardial infarction...
  101. ncbi Comparison of effects of bare metal versus drug-eluting stent implantation on biomarker levels following percutaneous coronary intervention for non-ST-elevation acute coronary syndrome
    C Michael Gibson
    TIMI Study Group, Cardiovascular Division, Brigham and Women s Hospital and Department of Medicine, Harvard Medical School, Boston, Massachusetts, USA
    Am J Cardiol 97:1473-7. 2006
    ..In conclusion, patients undergoing DES implantation achieved more reductions in periprocedural markers of inflammation and necrosis than patients receiving bare metal stents among those with non-ST-elevation acute coronary syndrome...